Placebo + Empagliflozin for heart failure

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 6 Nov 2017: Trial registered, NCT03332212
  2. 1 Mar 2018: Trial started, NCT03332212

The trials

NCT03332212: A Study That Looks at the Function of the Heart in Patients With Heart Failure Who Take Empagliflozin

State
Completed
Phase
Phase 3
People
72 taking part
Started
1 Mar 2018
Primary completion
21 May 2020
Arms
Cohort A (Empagliflozin + Placebo), Cohort B (Empagliflozin + Placebo)
Results
Posted on the registry
  1. 6 Nov 2017: Trial registered
  2. 1 Mar 2018: Trial started
  3. 28 May 2020: Trial completed
  4. 18 Jun 2021: Trial results posted

NCT05553938: Effects of Acute and Chronic Empagliflozin Heart Failure

State
Under way
Phase
Phase 1
People
60 taking part
Started
4 Aug 2023
Primary completion
8 May 2026
Arms
Placebo, Then Empagliflozin
Results
None posted
  1. 26 Sep 2022: Trial registered
  2. 4 Aug 2023: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.